Inovio Pharmaceuticals Inc stock page - price, fundamentals, dividends - iOCharts

Ticker
INO

Price
1.89
Stock movement up
+0.16 (9.25%)
Company name
Inovio Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
432.89M
Ent value
464.30M
Price/Sales
270.10
Price/Book
1.22
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-14.60%
1 year return
-80.02%
3 year return
-14.13%
5 year return
-24.92%
10 year return
0.95%
Last updated: 2022-07-01

DIVIDENDS

INO does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales270.10
Price to Book1.22
EV to Sales289.70

FINANCIALS

Per share

Loading...
Per share data
Current share count229.04M
EPS (TTM)-1.56
FCF per share (TTM)-1.07

Income statement

Loading...
Income statement data
Revenue (TTM)1.60M
Gross profit (TTM)1.40M
Operating income (TTM)-320.40M
Net income (TTM)-328.33M
EPS (TTM)-1.56
EPS (1y forward)-0.98

Margins

Loading...
Margins data
Gross margin (TTM)87.58%
Operating margin (TTM)-19990.90%
Profit margin (TTM)-20485.93%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash59.01M
Net receivables7.49M
Total current assets399.91M
Goodwill10.51M
Intangible assets2.50M
Property, plant and equipment16.70M
Total assets445.51M
Accounts payable39.52M
Short/Current long term debt33.65M
Total current liabilities59.36M
Total liabilities90.43M
Shareholder's equity355.09M
Net tangible assets344.57M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-224.72M
Capital expenditures (TTM)1.35M
Free cash flow (TTM)-226.07M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-92.47%
Return on Assets-73.70%
Return on Invested Capital-91.77%
Cash Return on Invested Capital-63.19%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.77
Daily high1.89
Daily low1.72
Daily Volume6.01M
All-time high191.00
1y analyst estimate5.00
Beta0.82
EPS (TTM)-1.56
Dividend per share-
Ex-div date28 Sep 2017
Next earnings date8 Aug 2022

Downside potential

Loading...
Downside potential data
INOS&P500
Current price drop from All-time high-99.01%-20.19%
Highest price drop-99.66%-56.47%
Date of highest drop19 Nov 20089 Mar 2009
Avg drop from high-91.15%-11.36%
Avg time to new high395 days12 days
Max time to new high5615 days1805 days
COMPANY DETAILS
INO (Inovio Pharmaceuticals Inc) company logo
Marketcap
432.89M
Marketcap category
Small-cap
Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Employees
317
Investor relations
SEC filings
CEO
Jong Kim
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated di...
July 1, 2022
This week's Lab Notes has items on a Chester County company's ongoing pursuit of approval for its lead drug candidate, a Bucks County company exploring its options after generating positive study resu...
July 1, 2022
Inovio Pharmaceuticals (NASDAQ: INO) stock rose slightly on an otherwise gloomy day for the wider market. Investors were cheered by the appointment of a new chief medical officer at their company. P...
June 27, 2022
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated di...
June 27, 2022
Once a problem confined to just one continent, Monkeypox is spreading and threatens to become a global issue. Since the United Kingdom first reported a confirmed Monkeypox case on May 7, many more cas...
June 9, 2022
It's more important than ever to make highly selective investment decisions with a struggling stock market, challenging economic issues, and dangerous geopolitical tensions. Inovio Pharmaceuticals en...
June 2, 2022
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
May 28, 2022
In this article, we discuss 10 small-cap stocks to sell now before recession begins. If you want to read about some more small-cap stocks to sell now before recession begins, go directly to 5 Small-Ca...
May 28, 2022
INOVIO (NASDAQ: INO) announced results from the company's novel Phase 1/2 trial of INO-5401 and INO-9012 in combination with PD-1 inhibitor Libtayo® (cemiplimab) in the treatment of newly diagnosed gl...
May 27, 2022
The outbreak still consists of fewer than a hundred cases, according to the World Health Organization.
May 23, 2022
Next page